Company news

Sino Biopharmaceutical Limited news in 2026

Sino Biopharmaceutical Limited's news releases, calls and decks from 2026, newest first.

View company

Voluntary announcement - phase ii clinical data of tq-A3334 "TLR7 agonist" presented at the 2026 aasld

November 8, 2026

Voluntary announcement - enter into partnership with Boehringer Ingelheim with potential total deal value of US$7 billion

November 4, 2026

Monthly return of equity issuer on movements in securities for the month ended 31 October 2026

November 1, 2026

Voluntary announcement - tq-A3334 "TLR7 agonist" and TQA3605 "core protein allosteric modulator" granted breakthrough therapy designation by cde

October 26, 2026

Voluntary announcement - data from two clinical studies of TQB2102 "HER2 biparatopic adc" presented at 2026 esmo

October 25, 2026

Next day disclosure return

October 22, 2026

Voluntary announcement - completion of all participants enrollment in the phase iii registrational clinical trial of TQC2731 injection "tslp monoclonal antibody" for chronic sinusitis with nasal polyps

October 20, 2026

Voluntary announcement - latest research results on tq-A3334 "TLR7 agonist" and bepirovirsen "aso" to be presented at 2026 aasld

October 14, 2026

Next day disclosure return

October 14, 2026

Next day disclosure return

October 13, 2026

Voluntary announcement - completion of all subjects enrollment in the phase iii registrational clinical trial of TQC3721 inhalation suspension "PDE3/4 inhibitor"

October 8, 2026

Monthly return of equity issuer on movements in securities for the month ended 30 September 2026

October 1, 2026

Voluntary announcement - enter into strategic biosimilars partnership with STADA

September 28, 2026

Notification letter and request form for non-registered shareholders

September 24, 2026

Notification letter and reply form for registered shareholders

September 24, 2026

2026 Interim report

September 24, 2026

Voluntary announcement - acceptance of new drug application for TQH2722 injection

September 15, 2026

Voluntary announcement - acceptance of new drug application for TQB2102 injection "HER2 bispecific adc"

September 15, 2026

Sino Biopharmaceutical Limited Unveils New Global Brand, SBP Group, to Accelerate International Expansion

August 19, 2026

Once-Yearly Dosing, Targeting Cardiovascular Disorders, First US Patient Enrolled in China-US Phase II Clinical Trial of Hygieia's Kylo-11

April 9, 2026

Sino Biopharm Releases 2025 Annual Results: Revenue and Net Profit Maintain Double-Digit Growth, Innovative Product Revenue Exceeds RMB 15 Billion

March 26, 2026

Positive on Dual Endpoints! CTTQ Pharma's Phase III Study of TQB3454 in Bile Duct Cancer Succeeds, Marketing Application to be Submitted

March 12, 2026

JPM 2026 | Sino Biopharm Leads in siRNA and Tumor Innovation Platforms, M&A Integration Unleashes Long-Term Growth Momentum

January 15, 2026

Decks in 2026